[Duloxetine. A new preparation for patients with urinary incontinence].
Stress Urinary Incontinence is a common symptom among women. The urethral closure is insufficient. Pelvic floor exercise can minish the symptoms, but many women need an operation. Duloxetine, a new drug, is believed to strengthen the contraction of the external urethral sphincter through central neuromodulation, resulting in enhanced urethral closure during the urine storage phase. In controlled studies a significant effect are found in women suffer from Stress Urinary Incontinence. Discontinuate rates for adverse events were high especially nausea and fatigue. The adverse event deminish after 4 weeks.
Walter
Steen
S
Urologisk Afdeling L, Odense Universitetshospital, DK-5000 Odense C. steen.walter@ouh.fyns-amt.dk
D018759:Adrenergic Uptake Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000068736:Duloxetine Hydrochloride; D005260:Female; D006801:Humans; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D013876:Thiophenes / Q000008:administration & dosage / Q000627:therapeutic use*; D001743:Urinary Bladder / Q000294:innervation; D014550:Urinary Incontinence, Stress / Q000188:drug therapy* / Q000503:physiopathology
D018759:Adrenergic Uptake Inhibitors; D000068736:Duloxetine Hydrochloride; D017367:Selective Serotonin Reuptake Inhibitors; D013876:Thiophenes